[
  {
    "ts": null,
    "headline": "AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised",
    "summary": "ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.",
    "url": "https://finnhub.io/api/news?id=665bb54d202d0def053ba5ff679d874d43999bab51b0937b298fad08b42453f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761933960,
      "headline": "AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised",
      "id": 137293662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.",
      "url": "https://finnhub.io/api/news?id=665bb54d202d0def053ba5ff679d874d43999bab51b0937b298fad08b42453f4"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?",
    "summary": "Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.",
    "url": "https://finnhub.io/api/news?id=b279a3d0aa930026ff6987354bef78a7d4427dcabe962d3bfb098de6b8c0df1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761933600,
      "headline": "Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?",
      "id": 137294551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.",
      "url": "https://finnhub.io/api/news?id=b279a3d0aa930026ff6987354bef78a7d4427dcabe962d3bfb098de6b8c0df1e"
    }
  },
  {
    "ts": null,
    "headline": "Appointment of Yves Decadt as Member of Poxel’s Board of Directors",
    "summary": "LYON, France, October 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors.",
    "url": "https://finnhub.io/api/news?id=4cc6078451ebb4f00640bb8260e2be8234322f630fd1f7116528bb06feb75c2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761933120,
      "headline": "Appointment of Yves Decadt as Member of Poxel’s Board of Directors",
      "id": 137279080,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "LYON, France, October 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors.",
      "url": "https://finnhub.io/api/news?id=4cc6078451ebb4f00640bb8260e2be8234322f630fd1f7116528bb06feb75c2d"
    }
  },
  {
    "ts": null,
    "headline": "I’m 65, itching to retire but only have $500K saved. I want $2K/month plus my Social Security — how can I swing this?",
    "summary": "Here are four options for supplementing your retirement.",
    "url": "https://finnhub.io/api/news?id=0595ce1375b38b69c1e30bb63d5d25d983409f7c20e7ae4ad763774596f2d252",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761928200,
      "headline": "I’m 65, itching to retire but only have $500K saved. I want $2K/month plus my Social Security — how can I swing this?",
      "id": 137294552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Here are four options for supplementing your retirement.",
      "url": "https://finnhub.io/api/news?id=0595ce1375b38b69c1e30bb63d5d25d983409f7c20e7ae4ad763774596f2d252"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.",
    "summary": "FEATURE   AbbVie stock traded slightly lower Friday as the biopharmaceutical giant reported mixed results across its drug portfolios in the third quarter. Adjusted earnings of $1.86 a share topped the $1.",
    "url": "https://finnhub.io/api/news?id=05775eb82c527aaf9b53fc389dbdf8ae36f1b928160854392932d9f0a156ab6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761913200,
      "headline": "AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.",
      "id": 137277301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "FEATURE   AbbVie stock traded slightly lower Friday as the biopharmaceutical giant reported mixed results across its drug portfolios in the third quarter. Adjusted earnings of $1.86 a share topped the $1.",
      "url": "https://finnhub.io/api/news?id=05775eb82c527aaf9b53fc389dbdf8ae36f1b928160854392932d9f0a156ab6b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Why Q3 Confirms Its Immunology Dominance",
    "summary": "AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ABBV stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=2cf08acf8bffde47895303fb70bac1b045d034f90b9bbef370a803bda96f3cba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761907191,
      "headline": "AbbVie: Why Q3 Confirms Its Immunology Dominance",
      "id": 137277814,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/939034648/image_939034648.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ABBV stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=2cf08acf8bffde47895303fb70bac1b045d034f90b9bbef370a803bda96f3cba"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage",
    "summary": "Broadcom, Johnson & Johnson, and Palantir headline Zacks' latest analyst picks, with AI growth, pharma innovation, and defense tech momentum driving their outlooks.",
    "url": "https://finnhub.io/api/news?id=dc2148f6768c66da83c616f2d5264d518a87f572360b9bdd7ad78af3135995f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761896940,
      "headline": "The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage",
      "id": 137277177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Broadcom, Johnson & Johnson, and Palantir headline Zacks' latest analyst picks, with AI growth, pharma innovation, and defense tech momentum driving their outlooks.",
      "url": "https://finnhub.io/api/news?id=dc2148f6768c66da83c616f2d5264d518a87f572360b9bdd7ad78af3135995f0"
    }
  }
]